FDA Approves First Drug for Rare Bone Disease After 30 Years

People with fibrodysplasia ossificans progressiva (FOP) watch helplessly as their muscles turn to bone, locking their bodies in place by their mid-20s. But on Wednesday, the FDA approved the first treatment that could change everything for them.

Regeneron Pharmaceuticals' drug Pasatru marks the end of a 30-year journey to find help for this ultra-rare disease. FOP causes bone to grow where it shouldn't, gradually imprisoning patients in their own bodies.

The disease typically forces people into wheelchairs by age 25 as excess bone accumulation locks up their limbs. Many patients don't survive past their 50s.

"You're almost completely stopping the new bone forming, and therefore their condition will not deteriorate," said Dr. Richard Keen of London's Royal National Orthopaedic Hospital, who led the medicine's pivotal trial. The hope is that patients can maintain their mobility and possibly extend their lives.

The approval represents a massive victory for the FOP community, who have waited generations for any treatment option. Until now, doctors could only manage symptoms and try to prevent flare-ups that trigger new bone growth.

Why This Inspires

This approval shows why patience and persistence in medical research matter. Thirty years is a long time to work toward a single goal, but for families affected by FOP, this medicine represents hope where none existed before.

The breakthrough also highlights how far rare disease research has come. Conditions that affect small numbers of people once attracted little attention, but companies and researchers increasingly recognize that every patient deserves a fighting chance.

For young people diagnosed with FOP today, the future looks dramatically different than it did just a few months ago.